At the same time, few new antibacterials are being discovered. There is a worldwide recognition regarding the danger of this situation. The urgency of the situation and the conviction that practices should change led the Société de Réanima-tion de Langue Française (SRLF) and the Société Française d'Anesthésie et de Réanimation (SFAR) to set up a panel of experts from various disciplines. These experts met for the first time at the end of 2012 and have since met regularly to issue the following 67 recommendations, according to the rigorous GRADE methodology. Five fields were explored: i) the link between the resistance of bacteria and the use of antibiotics in intensive care; ii) which microbiological data and how to use them to reduce antibiotic consumption; iii) how should antibiotic therapy be chosen to limit consumption of antibiotics; iv) how can antibiotic administration be optimized; v) review and duration of antibiotic treatments. In each institution, the appropriation of these recommendations should arouse multidisciplinary discussions resulting in better knowledge of local epidemiology, rate of antibiotic use, and finally protocols for improving the stewardship of antibiotics. These efforts should contribute to limit the emergence of resistant bacteria.
Introduction
Emerging resistance to antibiotics shows no signs of decline [1] . At the same time, few new antibacterials are being discovered [2] [3] [4] . There is worldwide recognition of the danger of this situation [5] [6] [7] .
Hospitalized patients are the first victims of the increasing resistance of bacteria. Those admitted to intensive care units are particularly affected [8] [9] [10] , often by species resistant to virtually all antibiotics [11] [12] [13] [14] .
The urgency of the situation and the conviction that practices should change (using new clinical data and technical advances) led the Société de Réanimation de Langue Française (SRLF) and the Société Française d'Anesthésie et de Réanimation (SFAR) to set up a panel of experts from various fields. This expert panel met for the first time at the end of 2012 and has since met regularly to issue the following recommendations, according to the rigorous methodology described below.
These recommendations are aimed at intensivists managing adult and paediatric patients. In the case of the latter, the literature is often poor. The section headings of the recommendations should therefore be taken as formulated for the care of adults. If they are valid also for children, this is specified.
Methodology
These recommendations were drawn up by an expert panel brought together by the SRLF and the SFAR. The various disciplines involved in the prescription of antibiotics in intensive care units (critical care, microbiology, infectious diseases, hospital hygiene, paediatrics) were represented.
Selection and organization of the expert panel
The selection of committee members was based on interest and expertise in specific aspects such as microbiology, infectious diseases, infection control, epidemiology etc. Executive committee members (CB, CM, ML and BM) were first chosen by the SRLF and the SFAR as was the expert panel coordinator (JPB). Then, the executive committee with the expert panel coordinator defined the questions or fields to be covered (Table 1) . They designated the experts in charge of each question. The latter had to disclose any financial or non-financial/academic competing interest before participating in that group.
Grading of recommendations
The grading of recommendations assessment, development and evaluation (GRADE) system was used to convey the recommendations [15, 16] .
A separate literature search was performed for each field. Experts worked with executive committee members to identify pertinent search terms that were included. The authors were asked to search a minimum of one general database (i.e. MEDLINE, EMBASE) and the Cochrane library. For each question, available evidence was summarized in the form of evidence tables. During all the recommendations process, these tables were shared online on a specific, dedicated server.
The authors were asked to follow the principles of the GRADE system to guide assessment of quality of evidence and to determine the strength of recommendations [15] . The GRADE system is based on a sequential assessment of the quality of evidence, followed by assessment of the balance between benefits and risks. Burden and cost are then considered, leading to development and grading of each recommendation. Keeping the rating of quality of evidence and strength of recommendation explicitly separate constitutes a crucial feature of the GRADE approach.
This system classifies quality of evidence as high (grade A), moderate (grade B), low (grade C) or very low (grade D). Randomized trials begin as high-quality evidence but may be downgraded owing to factors such as study limitations, inconsistent results, and indirectness of evidence, imprecision or possible reporting bias (Table 2) . Although well-done observational studies generally yield low quality of evidence, three factors may contribute to produce moderate or even high quality of evidence: large magnitude effect, plausible confounding, which would reduce a demonstrated effect, or dose-response gradient effect ( Table 2) .
The GRADE system classifies recommendations as strong (grade 1) or weak (grade 2). The factors influencing this determination are presented in Table 2 . The assignment of strong or weak is considered of greater clinical importance than a difference in letter level of quality of evidence. The committee assessed whether the desirable effects of adherence would outweigh the undesirable effects. The strength of a recommendation reflects the group's degree of confidence in that assessment. Thus, a strong recommendation in favour of an intervention reflects the panel's opinion that the desirable effects of adherence to a recommendation (beneficial health outcomes, lesser burden on staff and patients, and cost savings) will clearly outweigh the undesirable effects (harm to health, more burden on staff and patients, and greater costs). The potential drawbacks of making strong recommendations in the presence of low-quality evidence were taken into account. A weak recommendation in favour of an intervention indicates the judgment that the desirable effects of adherence to a recommendation probably will outweigh the undesirable effects, but the panel is not confident about these trade-offs either because some of the evidence is low quality (and thus uncertainty remains A strong recommendation is worded as 'we recommend' or 'must be done, must not be done' and a weak recommendation as 'we suggest' or 'should probably be done, should probably not be done'. Throughout the document are a number of statements that either follow graded recommendations or are listed as stand-alone numbered statements followed by 'ungraded' in parentheses (UG). For our group, these recommendations were not conducive for the GRADE process. Committee members were familiar with the GRADE system. Rules were discussed concerning assessing the body of evidence and committee members were available for advice throughout the process.
Subgroups agreed electronically on draft proposals that were then discussed with all the experts. The results of the discussion were incorporated into the next version of recommendations and again discussed with the whole group. Draft recommendations were then mailed to the group for vote.
The aim was not necessarily to reach a single and convergent opinion for all proposals, but rather to highlight points of agreement and points of disagreement or indecision. Each recommendation was then scored by each expert on a scale ranging from 1 (incomplete agreement) to 9 (complete agreement). The collective scoring was established using a methodology derived from the RAND/UCLA appropriateness method [18] : after elimination of the extreme values (outliers), the median and confidence interval of the scores were calculated. The median defined agreement between the experts when it was between 7 and 9, disagreement between 1 and 3 and indecision between 4 and 6. The agreement, disagreement or indecision were 'strong' if the confidence intervals were within one of three ranges, namely 1-3, 4-6 or 7-9, and 'weak' if they were out of these ranges. In the absence of strong agreement, the recommendations were reformulated and again scored with a view to achieving a better consensus.
Two rounds of scoring were therefore performed and the 67 recommendations presented below.
Conflict of interest policy
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Results
The different recommendations are presented below. For each field, the recommendations are listed with quality of evidence and strength in a dedicated table. The rationale is then summarized for each field but detailed argumentation and/or additional references can also be found as electronic supplementary material (ESM).
Q1: There is a link between the resistance of bacteria and the use of antibiotics in intensive care
Recommendations are presented in Table 3 . There was a strong agreement in the group for the first two statements. Nevertheless, it was decided that the literature data did not allow grading of these items, so they appear as 'ungraded' (UG) in the table.
Rationale
Antibiotic selection pressure is an important determinant of the emergence and spread of resistance to antibiotics.
Footnote 1 continued regarding the benefits and risks) or the benefits and downsides are closely balanced. A weak recommendation might also reflect uncertainty about whether the intervention represents a wise use of resources. Moreover, it is one of the few factors (with hand hygiene) that can be influenced or modified through practice. In intensive care, studies are above all of uncontrolled before-and-after design, the main focus of which is not always bacterial resistance [19] [20] [21] . A systematic review by Kaki et al. [22] confirms this trend. The conclusion can be drawn that bacteriological ecology in intensive care is (partially) dependent on the antibiotic policy of a given unit. It is worth stressing the importance of using local epidemiological data on antibiotic resistance because there are major disparities between European countries and those of other continents, notably North America. The susceptibility rate for given species has to be determined locally. But the actual frequency of patients infected by these given bacteria is almost as important.
The DDD should be considered separately from individual description of treatments. DDDs recommended by the World Health Organisation (WHO) often differ substantially from the doses actually used in intensive care, particularly in the case of b-lactam antibiotics. They artificially increase the consumption of antibiotics attributed to intensive care. Like all aggregate data, they have to be reduced to a common denominator, usually the number of days of hospitalization, a value easy to record in intensive care. Despite these imperfections, the DDD is the most useful parameter because it can be easily and quickly recorded and because, to some extent, it enables comparisons between intensive care units [23] .
Q2: Which microbiological data and how to use them to reduce antibiotic consumption?
Recommendations are presented in Table 4 . For this field, to grade the strength of recommendations, the group has paid particular attention to the resource use.
Sampling for diagnostic purposes must be done early, if possible before the onset of antibiotics administration. The quality of microbiological examinations depends on the information given to the laboratory, the choice and methods of sampling and the sample transport and storage conditions. Deep or invasive sampling is the most appropriate [24] and should enable de-escalation, which is facilitated if documentation is available [25, 26] .
For patients with ventilator-associated pneumonia (VAP), three studies compared the invasive strategy with 
1C
In the patients with ventilator-associated pneumonia (VAP), before the antibiotic treatment onset, we recommend collecting respiratory samples for quantitative culture, in order to reduce exposure to antibiotics
We recommend that the results of respiratory specimen Gram stain are communicated to the clinician without delay
In the absence of signs of severe VAP, if direct examination is negative, we suggest not initiating empirical antibiotic treatment
2C
In the presence of signs of severe VAP, we suggest starting antibiotic treatment based on result of direct examination (or empirically if direct examination is negative)
A first culture result should be available in the 24 h following sampling
UG
If the blood culture is positive, we recommend doing bacterial identification and antibiotic susceptibility testing directly using the blood culture bottle
1B
If the culture is positive, we suggest tailoring antibiotic treatment early after rapid bacterial identification by mass spectrometry
2C
In positive blood cultures with clustered Gram-positive cocci on direct examination, we recommend using rapid tests to detect the presence of S. aureus and to determine methicillin (oxacillin) susceptibility
1B
We recommend determining the minimum inhibitory concentrations, as recommended by the European Committee on antimicrobial susceptibility testing, and communicating them to clinicians
After discussion between microbiologist and clinician, we suggest determining the minimum inhibitory concentration for specific infected sites and bacterial species
1C
In the patients with community-acquired pneumonia, if urinary pneumococcal antigen is positive in adults, we suggest stopping antibiotics, considering intracellular bacteria. If there is no urinary pneumococcal antigen, diagnosis of pneumococcal pneumonia should not be discarded
2B
If there is urinary Legionella antigen, we suggest stopping the prescribed b-lactam. When there is no urinary Legionella antigen, the diagnosis of Legionella pneumonia should not be discarded quantitative cultures (bronchoalveolar lavage or protected specimen brush sampling) and the non-invasive strategy with qualitative or semi-quantitative cultures of tracheal aspirates. One study showed that invasive sampling reduced mortality and increased the number of days without antibiotic [27] . The second study showed that this practice reduced the duration of empirical antibiotic therapy, without increasing time on ventilation or morbidity and mortality [28] . The largest study did not confirm these results, but it did not use invasive sampling to guide antibiotic therapy [29] . The sensitivity of direct testing is closely associated with the quantity of bacteria present: between 10 3 and 10 5 bacteria/mL, 60 % of direct tests give positive findings. A meta-analysis indicated a negative predictive value of 91 % and a positive predictive value of 40 % for an approximately 30 % prevalence of VAP [30] .
Depending on the study, automated systems for liquid samples provide bacterial identification and antibiotic susceptibility results in 3-6 and 7-13 h, respectively. However, this means that the results become available outside laboratory hours. Real-time transmission of the results to clinicians demands reorganization of human resources [31] . Mass spectrometry provides identification in a few minutes, with 84-94 % agreement with conventional techniques.
Bacterial identification and antibiotic susceptibility testing using liquid directly from positive blood culture bottles can reduce by 20 % the consumption of antibiotics [32] . Bacterial identification is possible directly by mass spectrometry (average time 30 min) with good agreement (80-98 %) as compared with conventional methods, particularly for Gram-negative bacilli [33] . The time gained (1.2-1.5 days) enables earlier adaptation of antibiotic therapy in 35 % of patients with bacteraemia (vs. 21 % if adaptation is only done on reading of the Gram staining results), plus a 5.5-11.3 % increase, depending on the study, in the proportion of patients correctly treated [33] . Earlier bacterial identification and antibiotic susceptibility results in the case of bacteraemia reduce hospital stay and costs [34] .
Mass spectrometry can be used for bacterial identification in a few minutes, with 84-94 % agreement with conventional techniques. Bacterial identification enables adaptation of the antibiotic therapy even if the antibiotic susceptibility results are not yet known.
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) specifies the antibiotic-bacteria pairs for which the minimum inhibitory concentration (MIC) should be reported. The MIC should probably also be determined for particular infected sites (endocarditis, bone infections etc.) and for potentially resistant bacterial species (e.g. Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter, Staphylococci and glycopeptide antibiotics).
It is difficult to establish the impact of the use of urinary antigen tests [35] [36] [37] . In an interventional study, urinary antigen tests for Streptococcus pneumoniae and Legionella pneumophila reduced the prescription of broad-spectrum antibiotics, but at the price of a greater risk of clinical relapse [36] .
Q3: How should antibiotic therapy be chosen to limit consumption of antibiotics?
What impact does colonizaƟon status have on the choice of iniƟal anƟbioƟctreatment?
Recommendations are presented in Table 5 . The required constrained format has only a limited number of references. However, a more detailed argumentation with more numerous references can be found as ESM.
Rationale
To date, there is no randomized controlled study on reducing quantity or quality of antibiotic therapy using colonization data. Few teams perform surveillance cultures [38, 39] , but caution is needed because the prescription of empirical antibiotic therapy guided by tests on endotracheal aspirates (colonization) is not necessarily better than the application of guidelines [40] . Also, such practices could lead to the prescription of excessive antibiotic therapy based on a result reflecting colonization status. Recommendations are presented in Table 6 .
The use of carbapenems in intensive care is associated with the emergence of bacterial resistance [41, 42] . To preserve their efficacy, these molecules should be spared as much as possible [43] . Given the new EUCAST recommendations on MIC breakpoints (third-generation cephalosporin and aztreonam), based on pharmacokinetic-pharmacodynamic data, there are possible alternatives to carbapenems [44] , including b-lactam/b-lactamase inhibitor combinations [45] . In all cases, these adaptations are made taking into account the site and the microbiological data (MIC).
c)
When and how should use of quinolones be reduced?
Recommendations are presented in Table 7 .
Rationale
Fluoroquinolones are widely used because of their undeniable clinical value, good oral bioavailability and favourable diffusion in tissues. But their use is accompanied by numerous deleterious effects. The ecological consequences [46, 47] include the emergence of resistance to fluoroquinolones [21] by mutation of DNA gyrase or of topoisomerase, overexpression of efflux pumps or lack of permeability. Some of these mechanisms affect both Gram-negative bacilli and Grampositive cocci. They also affect the resistance of other classes of antibiotics. The emergence of MRSA associated with fluoroquinolones use should therefore be noted [48] . There is also an impact on intestinal flora, with the emergence of highly virulent Clostridium difficile [49] or the emergence and spread of extended-spectrum b-lactamase-producing Enterobacteriaceae [50, 51] .
Moreover, the toxicity and side effects of these antibiotics may be significant (tendinopathy, phototoxicity, hepatitis, QT prolongation), which led the European Medicines Agency (EMA) to issue warnings and restrictions for use. 
1B
Carbapenem should, however, be considered in patients with a combination of: A known history of colonization/infection by extendedspectrum b-lactamase-producing Enterobacteriaceae or by ceftazidime-resistant P. aeruginosa, determined within the last 3 months, whatever the sampling site, and Severe sepsis or septic shock
2D
In terms of empirical antimicrobial treatment, if a hospitalacquired severe bacterial infection is suspected, we recommend not prescribing carbapenem solely on the basis of the nosocomial nature of the infection, but rather considering the presence of at least two of the following criteria: Previous treatment with a third-generation cephalosporin, fluoroquinolones (including a single dose) or a piperacillintazobactam combination in the last 3 months, Carriage of extended-spectrum b-lactamase-producing Enterobacteriaceae or of ceftazidime-resistant P. aeruginosa, determined within the last 3 months, whatever the sampling site, Hospitalization during the last 12 months, Patient living in a nursing facility or in a long-term care facility for elderly and carrying an indwelling catheter and/or a gastrostomy tube, Ongoing epidemic episode of multidrug-resistant bacteria in the healthcare institution for which the only treatment option is carbapenem
1C
After documenting the bacterial infection, an alternative to carbapenems should be found, according to the infected site and after microbiologist and clinician interactions UG 
2C
We recommend not prescribing fluoroquinolones repeatedly in the same patient (take into account prescriptions of fluoroquinolones within the last 6 months, whatever the indication)
1B
We recommend not prescribing fluoroquinolones as empirical monotherapy in severe nosocomial infections
We recommend not prescribing fluoroquinolones for strains of Enterobacteriaceae that have acquired resistance to nalidixic acid and/or pipemidic acid
Recommendations are presented in Table 8 . As in previous sections, the reader can refer to the ESM for a wider list of included studies.
Rationale
Although some studies in the USA reported that up to 12 % of MRSA infections are community-acquired, this resistance is much less frequent in Europe. It is important to consider possible MRSA for treating severe infections in patients with MRSA discharged from hospital within the last year. Carriage of multidrug-resistant bacteria is increased in hospital-acquired infections. Antibiotic therapy within the last 6 months approximately doubles the risk of multidrug-resistant bacteria [52] . This risk is 12 % for MRSA in chronic haemodialysis patients [53] and 8.6-22 % in long-stay hospital patients [54, 55] . Half of patients are still MRSA carriers at 1 year. The estimated median time to MRSA clearance after hospital discharge is 8.5 months, and may be longer if the patients are still receiving care and antibiotic therapy [56] .
The proportion of MRSA among S. aureus is in constant decline and reached 25.5 % in 2012 in the French REA-RAISIN database, but the epidemiology varies greatly from one centre to another.
For CoNS, most international recommendations specify that only episodes with more than one positive blood culture should be taken into account. In a retrospective review, CoNS was found to be responsible for only four of 369 episodes of VAP in 1955 patients ventilated for more than 48 h [57] . Review of the diagnosis of VAP associated with CoNS and the search for an alternative diagnosis should therefore be routine.
Fowler et al. [58] in a subgroup analysis showed that a daptomycin dosage of 6 mg/kg/day was not inferior to standard therapy in the treatment of bacteraemia and rightsided endocarditis. In a single-centre nonrandomized study comparing daptomycin with vancomycin (median residual concentration 17.6 mg/L) in the treatment of MRSA bacteraemia with a vancomycin MIC [1 mg/L, there were fewer failures (20 vs. 48 %) and fewer deaths at 30 days (3.5 vs. 12.9 %) with daptomycin [59] . Despite the inherent limitations due to the nature of this study, these findings suggest that daptomycin should be used in this indication. High-dose daptomycin can be used to limit the emergence of resistant mutants even if the modalities of administration are not yet formally established.
A randomized study of 448 cases of nosocomial pneumonia [60] showed that the activity of linezolid was equivalent to that of vancomycin administered discontinuously. The clinical response in per protocol analysis was even better with linezolid (57.6 vs. 46.6 %; p = 0.042). However, the vancomycin plasma concentrations obtained were below those recommended. In addition, caution is required in drawing conclusions because of imbalances between the two groups.
The probability of survival in MRSA bacteraemia is greater if the vancomycin concentration over time divided by the vancomycin MIC for the bacterium is high (AUC 24h /MIC ratio [ 400). This target is very difficult to attain for vancomycin MICs above 1 mg/L [61] . However, the causal relation between high AUC/MIC and survival is not demonstrated. Recommendations are presented in Table 9 .
The authors of the Surviving Sepsis Campaign conclude that effective antibiotic therapy must be administered within 1 h of recognition of septic shock [62] . Several studies suggest that no more than 4 h should elapse between the admission and the first dose of antibiotic. However, a meta-analysis comparing early versus delayed antibiotics did not confirm this result [63] . The only prospective study included in this analysis even showed that early antibiotic administration did not shorten time to clinical stability [64] . In another literature analysis of the level of proof supporting a short time to first antibiotic dose in community-acquired pneumonia, the authors emphasized that reduction in the time between admission and the first dose was associated with antibiotic misuse, without mortality data sufficiently solid to counterbalance this risk.
On the basis of various studies, the 2009 French guidelines stipulated 3 h (ideally 1 h) as the time between admission and administration of the first antibiotic dose [65] .
Although the medical literature does not provide evidence, it seems that 'good practice' is to recommend optimization of the time to first antibiotic dose in the frail patients, such as those with post-splenectomy fever, neutropenic fever, and bacterial necrotizing dermatitis.
Recommendations are presented in Table 10 . As in previous sections, additional text and references are available online as ESM.
Critically ill patients (severe sepsis/septic shock, fluid challenges and vasopressors, haemorrhagic shock, burns, fever and neutropenia, acute kidney failure, continuous renal replacement therapy, morbid obesity, children) have major pathophysiological changes [66, 67] . These changes result in unpredictable between-and within-individual pharmacokinetic variability, in particular for hydrophilic antibiotics (aminoglycosides, vancomycin, b-lactam antibiotics) [68, 69] . Plasma and infected site antibiotic concentrations may be subtherapeutic, leading to clinical failure and development of bacterial resistance. Conversely, kidney and/or liver failure may result in toxic concentrations [70] . In children, this variability is increased by large age-related differences in volume of distribution, metabolism and elimination.
Pharmacokinetic/pharmacodynamic approaches show the value, in terms of clinical efficacy, toxicity and prevention of resistant mutants, of measuring the peak plasma concentration of aminoglycosides, which are hydrophilic antibiotics with concentration-dependent activity and a narrow therapeutic index [69] .
b)
When should therapeuƟc drug monitoring (TDM) of anƟmicrobials be performed? Table 9 Recommendations for field 4a: when is there a formal indication for antibiotics?
Recommendation
We recommend starting empirical antibiotic therapy within 1 h after recognition of septic shock
1B
In patients with suspected severe community-acquired pneumonia, before any antibiotic therapy, we suggest considering other diagnoses within the first 4 h after admission, thus avoiding unnecessary prescription
2B
In bacterial meningitis, we recommend to administer antibiotics within the 3 h after hospital admission, and ideally within 1 h
1B
The time to first antibiotic dose should probably be minimized in frail patients (asplenic or neutropenic patients) or in lifethreatening infections (bacterial necrotizing cellulitis, purpura fulminans, septic shock etc.) 
UG

2C
We suggest measuring the residual concentration of aminoglycosides in order to avoid toxicity associated with cumulative administrations, especially in patients with renal failure
In adults and children, we recommend determining the steadystate vancomycin concentration in the case of continuous infusion after a loading dose, or the residual concentration in the case of discontinuous administrations
1B
For assessing efficacy and toxicity, we suggest determining residual concentrations of broad-spectrum b-lactam antibiotics, in discontinuous and prolonged administration, or of the steady-state concentration in continuous infusion
2C
The bactericidal activity of vancomycin is AUC 24h / MIC-dependent. AUC 24h cannot be monitored routinely, but it correlates with residual concentration, which should therefore be measured. In discontinuous administration, the residual concentration must be determined before administration of the fourth dose. The target for residual concentration or steady-state concentration in continuous infusion is around 20 mg/L. It can be higher for the treatment of specific infected sites (central nervous system, cardiac vegetations or bone).
c)
Should certain methods be used to opƟmize anƟbioƟc administraƟon (route of administraƟon [intravenous, local], dosage)?
Recommendations are presented in Table 11 .
Rationale
For b-lactam antibiotics, the percentage time above the MIC, which varies according to the antibiotic (50-60 % for penicillins, 60-70 % for cephalosporins) [71] and the bacterium, is the best pharmacodynamic predictor of therapeutic efficacy. There is a clear and compelling rationale suggesting that the bactericidal activity of blactam antibiotics increases when the plasma concentrations increase to 4-6 times the MIC. However, few published data correlated achievement of these targets and the microbiological or clinical outcome of the patients [72] . In intensive care unit patients, Mohr et al. [73] suggested that a percentage time above the MIC of 100 % was associated with a C min /MIC ratio above 5 as a pharmacodynamic target for b-lactam antibiotics. Li et al. [74] confirmed this target, showing that this ratio is predictive of clinical success in the treatment of lower respiratory tract infection. Pharmacokinetic studies and modelling data agree: the administration of b-lactam antibiotics by continuous or prolonged (3 or 4 h) intravenous infusion increases the time spent above the MIC between two administered doses. Several studies suggested that prolonged infusion (3 or 4 h) of b-lactam antibiotics (cefepime, piperacillintazobactam, carbapenems) was associated with mortality reduction. Lastly, in a meta-analysis, Falagas et al. [75] showed 10.8 % mortality in patients treated by prolonged infusion of carbapenems or piperacillin-tazobactam, compared with 16.8 % in patients treated by intermittent perfusion (p = 0.03).
Several studies on ICU patients showed that continuous infusion of piperacillin-tazobactam, meropenem, ticarcillin-clavulanate, or ceftazidime produced plasma concentrations above the MIC more frequently than intermittent infusion. On the other hand, evaluations, including meta-analyses, of the clinical benefit of continuous intravenous infusion of b-lactam antibiotics did not show the previously mentioned theoretical pharmacokinetic advantage of this mode of administration. Failure to demonstrate the greater efficacy of continuous infusion may stem from methodological considerations, instability of the antibiotics, particularly penems, an inoculum effect or concentrations that are too low at the site of the infection.
Recent in vitro and clinical studies show that an AUC 24h /MIC ratio greater than 400 is predictive of the clinical efficacy of vancomycin treatment of pneumonia and MRSA bacteraemia. Clinical studies directly comparing continuous and intermittent intravenous infusion of vancomycin are contradictory [76] . However, continuous infusion does achieve target plasma concentrations more rapidly and limits the number of blood assays as well as the cost of treatment. In a Monte Carlo simulation study, in patients with severe sepsis, a loading dose of 35 mg/kg seems necessary to quickly reach a concentration of approximately 20 mg/L, followed by continuous infusion of 35 mg/kg to maintain this target concentration [77] .
In vitro and animal studies showed that the development of bacterial resistance is affected by antibiotic concentrations. Some pharmacodynamic variables (AUC/ MIC, peak/MIC, AUC/mutant prevention concentration, 
Recommendations
Very few studies offer direct, consistent arguments which allow one to assess the balance between the benefits and risks of using antibiotic combinations. Thus, the group issued ungraded statements. These are presented in Table 12 .
Rationale
Monotherapy might be sufficient for VAP on two conditions: time to onset from intubation of less than 7 days and the patient has received no previous recent antibiotic therapy. Length of hospital stay before intubation should also be considered. This 'monotherapy' approach should probably be extended to all hospitalacquired pneumonia without risk factors for multidrugresistant bacteria. Despite a low level of evidence, empirical treatment with a combination of antibiotics is usually recommended in the most critically ill (septic shock) or frail (blood cancer) patients, especially as they are at risk of infection by multidrug-resistant bacteria [62, 79] . However, even in frail patients, there should be a collective understanding of the fundamental importance of rational use of these combinations of antibiotics in order to avoid the emergence of multidrug-resistant bacteria [80] .
Q5: Review and duration of antibiotic treatments
Recommendations are presented in Table 13 .
Rationale
Few studies evaluated strategies for shortening the length of antibiotic treatments in intensive care units. Several strategies have been used: empirical reduction of treatment duration [81] , short course of empirical antibiotic therapy [82] and daily assay of procalcitonin [83] .
Studies showed that the duration of antibiotic therapy is reduced by following recommendations to interrupt antibiotic therapy when procalcitonin plasma concentrations decrease by 80-90 % from the initial value or below a threshold, most often 0.5 ng/mL [84] . Some of these studies included patients with all types of infections in intensive care units, but most focused on lower respiratory tract infections. Lastly, it should be noted that immunocompromised patients (neutropenia, blood We suggest using procalcitonin to guide the interruption of antibiotic therapy in intensive care unit patients, especially those with lower respiratory tract infections. When plasma procalcitonin concentration is below 0.5 ng/mL or has decreased by over 80 % from the peak value, antibiotic treatment can be stopped
2B
Regarding reassessment, we recommend implementing local recommendations in order to reduce antibiotic exposure
1B
We suggest assaying procalcitonin every 48-72 h after day 3, to reduce the length of antibiotic therapy
2B
When the initial antibiotic treatment is adequate for nonimmunosuppressed patients with ventilator-associated pneumonia, we suggest limiting the total duration of treatment to 8 days, irrespective of the causative organisms
Outside particular clinical situations, we recommend limiting treatment of a community-acquired infection to 5-7 days 1B Apart from S. aureus bacteraemia, we recommend limiting treatment of catheter-associated bacteraemia to 5-7 days if the blood cultures become negative in the first 3 days of treatment, if the catheter has been removed and in the absence of secondary infected sites
1B
We recommend organizing, in each intensive care unit, a regular (e.g. at least weekly) multidisciplinary staff meeting in order to improve the quality of antibiotic treatment and the rate of de-escalation and to limit the antibiotic use
We recommend implementing antibiotic treatment protocols in order to improve the patient outcomes and to limit the emergence of resistance 1C disease, organ transplantation, receiving immunosuppressive treatment) were excluded from these studies. Four randomized controlled studies compared two fixed treatment durations in non-immunocompromised adult patients with VAP. A fifth study, in neonatology, concerned bacteraemia. Other studies compared strategies using antibiotic therapy duration guided by clinical progression, biomarker kinetics or the use of antibiotic therapy protocols.
In VAP identified by microbiological criteria, 8-day compared with 15-day antibiotic therapy did not reduce 28-day survival, including when the causative organism was a non-fermenting Gram-negative bacillus (23 vs. 30 %, respectively). Relapse rate did not differ between the two strategies, except in the case of non-fermenting Gram-negative bacilli: 21/64 (32.8 %) in the 8-day group versus 12/63 (19 %) in the 15-day group [81] .
In non-immunocompromised patients without criteria of severe disease who have an uncomplicated communityacquired respiratory, intra-abdominal, or urinary infection of satisfactory clinical progression in the first 5 days, 5-to 7-day antibiotic therapy does not involve a greater risk of treatment failure than longer antibiotic therapy, including in patients with bacteraemia [85] . Apart from a S. aureus bacteraemia, or from a complicated bacteraemia, treatment should probably be limited to 5-7 days for a catheter-related bacteraemia if blood cultures become negative in the first 3 days of treatment and if the catheter has been removed [86, 87] .
The advantages of a specialized consultation (infectious diseases physicians) with the intensive care unit team are still open to debate. Five nonrandomized, singlecentre, before-and-after studies examining this question have evaluated the consumption of antibiotics, the appropriateness of the antibiotics prescribed compared with the recommendations, the increasing cost of antibiotics and in some cases mortality [88] .
There are no intensive care units studies that specifically assess the impact of antibiotic therapy protocols on resistance. There are only six studies (five of which are prospective before-and-after studies; no randomized studies) of low level of evidence. They suggest that the use of protocols improves the outcomes of patients and limits the emergence of resistance to antibiotics.
Discussion
These guidelines are aimed at reducing the spread of multidrug-resistant pathogens related to the overuse of antibiotics in intensive care units. The multidisciplinary expert panel selected 67 relevant recommendations that should support the decision to improve antibiotic stewardship at the bedside. These guidelines should facilitate the intensivist decisions for avoiding unnecessary antibiotic initiation, using narrow-spectrum antibiotics if possible, and interrupting early antibiotics. In contrast, patients requiring antibiotics should receive an adequate, early and efficient treatment. This strategy should minimize the development of resistance and offset the lack of new molecules. As experts, our role now is to convey these guidelines in each institution.
The first strength of these guidelines is the multidisciplinary nature of the expert panel group. Thus, adult intensivists, infectious disease specialists, epidemiologists and microbiologists discussed together throughout the elaboration process. Paediatric intensivists have also participated to produce recommendations for the specific paediatric population. The second strength is the adhesion to a meticulous process of methodology. The literature analysis, the elaboration of summaries of evidence and then the determination of the strength of the recommendations followed the GRADE methodology (see ''Methodology'' section).
However, one can discuss several limitations. Detractors can note a lack of details, making it difficult to transfer these guidelines in their routine practice. For instance, we did not detail the rules for adapting the antibiotic dosages in patients with renal failure. The readers are invited to refer back to recent papers [67] [68] [69] . De-escalation in real-life practice remains unclear, probably reflecting the lack of strong agreement between experts [9, 25, 26, [89] [90] [91] [92] [93] . Several aspects of our practice were not reported in the guidelines. The role of historical molecules (fosfomycin, minocycline etc.) could have been expanded [4] . The experts, probably as a result of their routine practice, did not consider entirely these old antibiotics. Aerosolizing of antibiotics was not developed, whereas there is a substantial amount of data on such a strategy [94] [95] [96] . However, in routine, aerosol antibiotics remain a relatively rare practice. We probably did not stress enough the need to avoid most prophylactic antibiotics. That was a weakness of the guidelines. One should nevertheless note that strategies based on the use of selective digestive decontamination resulted in a large decrease of antibiotic use [97] . The goal of our group was not to be exhaustive but to produce a few recommendations that were eligible in routine practice. Finally, a few recommendations may seem provocative for the readers. For example, the duration of treatment for pseudomonal infections might be questionable [98] . Our goal was consistently to encourage the reduction of antibiotic use, and we analysed the literature in this single way. In the ESM, the readers will find the argumentation based on our data assessment.
We reported above the guidelines as stated by the expert panel group. According to our methodology, we cannot change the content and meaning of each recommendation. We acknowledge that some recommendations are a matter of debate.
To date, the challenge is to diffuse, improve knowledge and implement these guidelines. In each institution, their appropriation should stimulate multidisciplinary discussions resulting in better knowledge of local epidemiology, rate of antibiotic use and finally protocols for improving the stewardship of antibiotics.
We hope these efforts will contribute to limit the emergence of resistant bacteria, and we are committed to assess their impact on this issue.
Conflicts of interest
The process for reporting conflicts of interest (COI) of the organizing committee members and of the experts is described in the ''Methodology'' section. Finally, during the manuscript writing final process, authors were again asked to declare whether they have or not any COI to disclose. Experts and organizing committee members indicate that they have no COI in particular that they have no financial relationship with the organization that sponsored the research. 
